Q1 EPS Forecast for CARGO Therapeutics Boosted by Analyst

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Equities researchers at William Blair raised their Q1 2025 EPS estimates for CARGO Therapeutics in a research note issued on Thursday, January 30th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($0.66) per share for the quarter, up from their prior estimate of ($0.95). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.74) per share. William Blair also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.77) EPS.

CARGO Therapeutics (NASDAQ:CRGX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.26.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group lowered shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $32.00 to $3.00 in a report on Thursday, January 30th. Piper Sandler lowered shares of CARGO Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $34.00 to $4.00 in a report on Thursday, January 30th. Chardan Capital lowered shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. lowered shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a report on Thursday, January 30th. Finally, HC Wainwright lowered shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $15.00.

CARGO Therapeutics Stock Performance

Shares of NASDAQ:CRGX opened at $3.70 on Monday. The firm has a market cap of $170.31 million, a PE ratio of -0.87 and a beta of 2.12. CARGO Therapeutics has a 52 week low of $3.00 and a 52 week high of $33.92. The firm’s fifty day moving average is $14.02 and its 200-day moving average is $17.12.

Hedge Funds Weigh In On CARGO Therapeutics

Institutional investors have recently made changes to their positions in the stock. Brooklyn Investment Group acquired a new position in shares of CARGO Therapeutics during the fourth quarter valued at about $27,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of CARGO Therapeutics during the fourth quarter worth about $141,000. BNP Paribas Financial Markets increased its position in shares of CARGO Therapeutics by 437.8% during the third quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock worth $211,000 after acquiring an additional 9,311 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of CARGO Therapeutics during the third quarter worth about $234,000. Finally, JPMorgan Chase & Co. increased its position in shares of CARGO Therapeutics by 74.9% during the third quarter. JPMorgan Chase & Co. now owns 15,007 shares of the company’s stock worth $277,000 after acquiring an additional 6,426 shares in the last quarter. Institutional investors and hedge funds own 93.16% of the company’s stock.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.